我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

2087例痛风患者合并症及并发症的回顾性研究*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2021年05期
页码:
19-24
栏目:
临床研究
出版日期:
2022-09-20

文章信息/Info

Title:
A Retrospective Study of 2087 Patients with Gout Co-morbidity and Complications
文章编号:
1000 - 2723(2021)05- 0019 - 06
作者:
杨显娜1张昊喆1晏蔚田1刘念1王兴强2唐海倩1凌丽1孟凡雨1朱军2彭江云2△
(1.云南中医药大学第一临床医学院,云南 昆明 650011;2.云中医药大学第一附属医院,云南 昆明 650021)
Author(s):
YANG Xianna1 ZHANG Haozhe1 YAN Weitian1 WANG Xingqiang2 LIU Nian1 TANG Haiqian1LING Li1 MENG Fanyu1 ZHU Jun2 PENG Jiangyun2
(1. The First Clinical Medical College of Yunnan University of Chinese Medicine, Kunming 650011, China;2. The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650021, China)
关键词:
痛风回顾性研究合并症并发症危险因素
Keywords:
gout retrospective study co-morbidity complications risk factors
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2021.05.004
文献标识码:
A
摘要:
目的 调查住院痛风患者合并症及并发症的临床特点,并分析其影响因素。方法 采用回顾性的研究方法对2016年1月-2021年6月于云南省中医医院风湿科住院的2 087例痛风患者的人口学信息、病史、实验室检查等资料进行统计,分析合并症及并发症的分布情况及相关影响因素。结果 痛风患者合并症及并发症总的患病率为88.88%。合并症主要为代谢性疾病:高脂血症360例(17.25%)、糖尿病310例(14.85%)、脂肪肝731例(35.03%);心血管疾病:高血压1 015例(58.63%)、冠心病220例(9.85%)、冠状动脉钙化86例(4.12%);肺部损害:肺结节191例(9.15%)、肺间质纤维化35例(4.12%);其他合并症:骨关节炎667例(31.96%)、肝损伤109例(5.22%)。并发病主要为肾脏疾病:肾结石389例(18.64%)、痛风性肾病244例(11.69%)、肾衰竭179例(8.58%)。影响合并症和并发症发生的危险因素较多,包括年龄、职业、长病程、血沉、C反应蛋白、低密度脂蛋白、高密度脂蛋白、甘油三酯、尿酸、肌酐等。结论 痛风患者合并症及并发症发病率高达88.88%。合并症中最多见的是代谢性疾病,其中脂肪肝发病率最高;并发症以肾脏疾病最多见,以肾结石发病率最高。年龄、职业、长病程、血沉、C反应蛋白等是其重要的危险因素。
Abstract:
Objective To investigate the clinical characteristics of co-morbidity and complications diseases of hospitalized patients with gout, and analyze the factors that can contribute to them. Methods The demographic information, medical history, laboratory examination and other data of 2087 gout patients hospitalized in the Yunnan Provincial Hospital of Traditional Chinese Medicine from January 2016 to June 2021 were analyzed statistically in order to get the distribution of co-morbidity and complications diseases, along with analyzing the affecting factors. Results According to the investigation, it was found that the total prevalence of co-morbidity and complications diseases in patients with gout was 88.88%. The metabolic diseases shared the most portion in co-morbidity, including hyperlipidemia in 360 cases (17.25%), diabetes mellitus in 310 cases (14.85%), fatty liver in 731 cases(35.03%); cardiovascular diseases: hypertension in 1015 cases(58.63%), coronary atherosclerotic heart disease in 220 cases(9.85%), coronary artery calcification in 86 cases(4.12%); lung damages: pulmonary nodules in 191 cases(9.15%), pulmonary fibrosis in 35 cases(4.12%); other co-morbidity: osteoarthritis in 667 cases (31.96%) and liver injury in 109 cases (5.22%). The renal diseases were the most common complications diseases, including renal calculi in 389 cases (18.64%), gouty nephropathy in 244 cases(11.69%), and renal failure in 179 cases(8.58%). There are many risk factors affecting the occurrence of co-morbidity and complications diseases, including age, occupation, long course of disease, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), low-density lipoprotein, high-density lipoprotein, triglyceride, uric acid(UA), creatinine(Cre), etc. Conclusion The incidence of co-morbidity and complications diseases in gout patients is as high as 88.88%. The most common co-morbidity are metabolic diseases, among which the incidence of fatty liver is the highest; the most common complications diseases are renal diseases, among which the incidence of renal calculi is the highest. Age, occupation, long course of disease, ESR, and CRP are important risk factors.

参考文献/References

[1] 中华中医药学会风湿病分会. 痛风和高尿酸血症病证结合诊疗指南[J]. 中医杂志,2021,62(14):1276-1288.
[2] BARDIN T,RICHETTE P. Impact of comorbidities on gout and hyperuricaemia:an update on prevalence and treatment options[J]. BMC Med,2017,15(1):123.
[3] KUO C F,LUO S F. Gout:Risk of premature death in gout unchanged for years[J]. Nat Rev Rheumatol,2017,13(4):200-201.
[4] CULLETON B F,LARSON M G,KANNEL W B,et al. Serum uric acid and risk for cardiovascular disease and death:the Framingham Heart Study[J]. Ann Intern Med,1999,131(1):7-13.
[5] VAN DURME C M,SPAETGENS B,BOONEN A,et al. Risk of vascular disease with gout:overadjustment of the statistical analyses?[J]. Ann Rheum Dis,2015,74(1):e9.
[6] RICHETTE P,CLERSON P,P?魪RISSIN L,et al. Revisiting comorbidities in gout:a cluster analysis[J]. Ann Rheum Dis,2015,74(1):142-147.
[7] 中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13.
[8] 徐凤玲,张亚明,薛梅. 建议规范使用“合并症”与“并发症”[J]. 中华围产医学杂志,2014,17(4):248.
[9] 刘念,张玲,李兆福,等. 痛风“清热通络、健脾渗湿”分期治疗研究荟萃[J]. 云南中医学院学报,2020,43(3):91-95.
[10] CHOI H K,FORD E S,LI C,et al. Prevalence of the metabolic syndrome in patients with gout:the Third National Health and Nutrition Examination Survey [J]. Arthritis Rheum,2007,57(1):109-115.
[11] RASHEED H,HUGHES K,FLYNN T J,et al. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels[J]. Circ Cardiovasc Genet,2014,7(6):830-837.
[12] RHO Y H,LU N,PELOQUIN C E,et al. Independent impact of gout on the risk of diabetes mellitus among women and men:a population-based,BMI-matched cohort study[J]. Ann Rheum Dis,2016,75(1):91-95.
[13] PEREZ-RUIZ F,MART?魱NEZ-INDART L,CARMONA L,et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout[J]. Ann Rheum Dis,2014,73(1):177-182.
[14] PAN A,TENG G G,YUAN J M,et al. Bidirectional Association between Self-Reported Hypertension and Gout:The Singapore Chinese Health Study[J]. PLoS One,2015,10(10):e0141749.
[15] MCADAMS-DEMARCO M A,MAYNARD J W,BAER A N,et al. Hypertension and the risk of incident gout in a population-based study:the atherosclerosis risk in communities cohort[J]. J Clin Hypertens(Greenwich),2012, 14(10):675-679.
[16] 张开富,刘岚,韩友琴. 痛风的肺部合并症[J]. 中华结核和呼吸杂志,2000,23(6):361-363.
[17] YOKOSE C,CHEN M,BERHANU A,et al. Gout and osteoarthritis:associations,pathophysiology,and therapeutic implications[J]. Curr Rheumatol Rep,2016,18(10):65.
[18] ROUGHLEY M J,BELCHER J,MALLEN C D,et al. Gout and risk of chronic kidney disease and nephrolithiasis:meta-analysis of observational studies[J]. Arthritis Res Ther,2015,17(1):90.
[19] YU K H,KUO C F,LUO S F,et al. Risk of end-stage renal disease associated with gout:a nationwide population study[J]. Arthritis Res Ther,2012,14(2):R83.
[20] YU T F,GUTMAN A B. Study of the paradoxical effects of salicylate in low,intermediate and high dosage on the renal mechanisms for excretion of urate in man[J]. J Clin Invest,1959,38(8):1298-1315.
[21] CHOI H K,SORIANO L C,ZHANG Y Q,et al. Antihypertensive drugs and risk of incident gout among patients with hypertension:population based case-control study[J]. BMJ,2012,344:d8190.
[22] MUSTARD J F,MURPHY E A,OGRYZLO M A,et al. Blood coagulation and platelet economy in subjects with primary gout[J]. Can Med Assoc J,1963,89(24):1207-1211.
[23] TAKAHASHI S,MORIWAKI Y,YAMAMOTO T,et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism[J]. Ann Rheum Dis,2003,62(6):572-575.
[24] VALLON V,THOMSON S C. Targeting renal glucose reabsorption to treat hyperglycaemia:the pleiotropic effects of SGLT2 inhibition[J]. Diabetologia,2017,60(2):215-225.

备注/Memo

备注/Memo:
收稿日期: 2021 - 08- 23
* 基金项目: 国家中医临床研究基地项目(国中医药科技函[2018]131号);国家自然科学基金(81760868);云南省科技厅-云南中医学院应用基础研究联合专项(2019FF002[082]);云南省高校中医风湿免疫病重点实验室(2018YGZ01);民族医药防治重大疾病诊疗方案及经典方剂安全性有效性评价研究(2017YFC1704005);云南省中医(风湿病)临床医学研究中心项目(202102AA310006)
第一作者简介: 杨显娜(1997-),女,在读硕士研究生,研究方向:中医内科学风湿病方向。
△通信作者: 彭江云,E-mail: pengjiangyun@126.com
更新日期/Last Update: 1900-01-01